Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study.

Sarkar S, Jiang Z, Evon DM, Wahed AS, Hoofnagle JH.

J Hepatol. 2012 Nov;57(5):946-52. doi: 10.1016/j.jhep.2012.06.030. Epub 2012 Jul 1.

2.

Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.

Galán RJ, Cidoncha EC, Martin MF, Rodriguez CC, Almeida CV, Verdugo RM.

J Manag Care Pharm. 2013 Jul-Aug;19(6):448-53.

3.

Efficacy and factors influencing treatment with peginterferon alpha-2a and ribavirin in elderly patients with chronic hepatitis C.

Yu JW, Sun LJ, Kang P, Yan BZ, Zhao YH.

Hepatobiliary Pancreat Dis Int. 2012 Apr;11(2):185-92.

PMID:
22484588
4.
5.

Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.

Rosen I, Kori M, Eshach Adiv O, Yerushalmi B, Zion N, Shaoul R.

World J Gastroenterol. 2013 Feb 21;19(7):1098-103. doi: 10.3748/wjg.v19.i7.1098.

6.

Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.

Yamada G, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T.

Clin Drug Investig. 2008;28(1):9-16. Erratum in: Clin Drug Investig. 2008;28(4):210.

PMID:
18081356
7.

Sustained virological response based on the week 4 response in hepatitis C virus genotype 1 patients treated with peginterferons α-2a and α-2b, plus ribavirin.

Dogan UB, Akin MS, Yalaki S.

Eur J Gastroenterol Hepatol. 2013 Nov;25(11):1317-20. doi: 10.1097/MEG.0b013e328362797b.

PMID:
23680912
8.

Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C.

Hauser G, Awad T, Brok J, Thorlund K, Štimac D, Mabrouk M, Gluud C, Gluud LL.

Cochrane Database Syst Rev. 2014 Feb 28;(2):CD005441. Review.

PMID:
24585509
10.

Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment.

Reddy KR, Shiffman ML, Morgan TR, Zeuzem S, Hadziyannis S, Hamzeh FM, Wright TL, Fried M.

Clin Gastroenterol Hepatol. 2007 Jan;5(1):124-9. Epub 2006 Dec 28.

PMID:
17196435
11.

Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial.

Liu CH, Liu CJ, Huang CF, Lin JW, Dai CY, Liang CC, Huang JF, Hung PH, Tsai HB, Tsai MK, Lee CY, Chen SI, Yang SS, Su TH, Yang HC, Chen PJ, Chen DS, Chuang WL, Yu ML, Kao JH.

Gut. 2015 Feb;64(2):303-11. doi: 10.1136/gutjnl-2014-307080. Epub 2014 Apr 19.

PMID:
24747867
12.

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.

Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, Peters MG, Koziel MJ, Bhan AK, Alston B, Colquhoun D, Nevin T, Harb G, van der Horst C; AIDS Clinical Trials Group A5071 Study Team.

N Engl J Med. 2004 Jul 29;351(5):451-9.

13.

Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.

Perry CM.

Drugs. 2012 Mar 26;72(5):619-41. doi: 10.2165/11208370-000000000-00000. Review.

PMID:
22439668
14.

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J.

N Engl J Med. 2002 Sep 26;347(13):975-82.

15.

Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial.

Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, Hezode C, Hirschfield GM, Jacobson I, Nikitin I, Pockros PJ, Poordad F, Scott J, Lenz O, Peeters M, Sekar V, De Smedt G, Sinha R, Beumont-Mauviel M.

Gastroenterology. 2014 Feb;146(2):430-41.e6. doi: 10.1053/j.gastro.2013.10.058. Epub 2013 Nov 1.

PMID:
24184810
16.

Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.

Buti M, Agarwal K, Horsmans Y, Sievert W, Janczewska E, Zeuzem S, Nyberg L, Brown RS Jr, Hézode C, Rizzetto M, Paraná R, De Meyer S, De Masi R, Luo D, Bertelsen K, Witek J.

Gastroenterology. 2014 Mar;146(3):744-753.e3. doi: 10.1053/j.gastro.2013.11.047. Epub 2013 Dec 4.

17.

Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b.

Mach TH, Cieśla A, Warunek W, Janas-Skulina U, Cibor D, Owczarek D, Ciećko-Michalska I.

Pol Arch Med Wewn. 2011 Dec;121(12):434-9.

18.

Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study.

Berak H, Laskus T, Kołakowska-Rządzka A, Wasilewski M, Stańczak JJ, Bardadin K, Walewska-Zielecka B, Horban A.

Adv Med Sci. 2014 Sep;59(2):261-5. doi: 10.1016/j.advms.2014.01.005. Epub 2014 Jun 9.

PMID:
25117425
19.

Impact of sex on virologic response rates in genotype 1 chronic hepatitis C patients with peginterferon alpha-2a and ribavirin treatment.

Yu JW, Sun LJ, Zhao YH, Kang P, Yan BZ.

Int J Infect Dis. 2011 Nov;15(11):e740-6. doi: 10.1016/j.ijid.2011.05.018. Epub 2011 Jul 30.

20.

Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection.

Sperl J, Frankova S, Senkerikova R, Neroldova M, Hejda V, Volfova M, Merta D, Viklicky O, Spicak J, Jirsa M.

World J Gastroenterol. 2015 May 14;21(18):5496-504. doi: 10.3748/wjg.v21.i18.5496.

Supplemental Content

Support Center